TABLE 3.

Median progression-free survival (mPFS) for combined immunotherapy and antiangiogenesis therapy with or without chemotherapy.

Group	No. of studies	No. of patients	Pooled PFS (95% CI), months
Overall	15	1,438	6.83 (5.53–8.13)
A + I	11	782	5.89 (4.58–7,19)
A + I + chemo	4	656	8.78 (6.63–10.93)
First-line therapy
A + I	2	584	10.9 (1.81–19.98)
A + I + chemo	3	653	9.47 (6.45–12.49)
Subsequent-line therapy
A + I	8	198	5.08 (4.01–6.15)
A + I + chemo	2	182	8.13 (5.00–11.26)
Anti-PD-1 therapy
A + I	7	623	5.90 (5.00–6.79)
A + I + chemo	3	300	8.87 (4.88–12.85)
Anti-PD-L1 therapy
A + I	4	159	7.07 (3.41–10.72)
A + I + chemo	1	356	8.40 (7.45–9.35)
Antiangiogenic TKIs
A + I	7	435	5.95 (5.11–6.80)
A + I + chemo	-	-	-
Antiangiogenic mAbs
A + I	4	94	7.51 (3.14–11.88)
A + I + chemo	4	656	8.78 (6.63–10.93)
EGFR mutation-positive
A + I	1	40	3.2 (0.75–5.65)
A + I + chemo	2	182	8.13 (5.00–11.26)
EGFR mutation-negative
A + I	10	742	6.0 (5.34–6.66)
A + I + chemo	3	653	9.47 (6.45–12.49)

95% CI, 95% confidence interval; A + I + chemo, antiangiogenic agents combined with ICIs with chemotherapy; A + I, antiangiogenic agents combined with ICIs; ICIs, immune checkpoint inhibitors; Anti-PD-1, programmed cell death protein-1 inhibitor; Anti-PD-L1, programmed cell death ligand-1 inhibitor; mAbs, monoclonal antibodies; TKIs, tyrosine kinase inhibitors.